Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval
- 31 October 2013
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 13 (5), 530-533
- https://doi.org/10.1016/j.clml.2013.03.017
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009Cancer, 2009
- Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemiaAmerican Journal of Hematology, 2009
- Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in miceLeukemia, 2009
- Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndromeLeukemia & Lymphoma, 2009
- BCR-ABLT315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?Leukemia, 2007
- Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapyCancer, 2007
- Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinibCancer, 2005
- Results of triple therapy with interferon‐alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phaseCancer, 2003
- HomoharringtonineCancer, 2001
- Cephalotaxine Esters: Antileukemic Advance or Therapeutic Failure?JNCI Journal of the National Cancer Institute, 1988